Aquestive Therapeutics Price To Operating Cash Flows Ratio Over Time
| AQST Stock | USD 4.51 0.23 4.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aquestive Therapeutics Performance and Aquestive Therapeutics Correlation. Aquestive |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aquestive Therapeutics. If investors know Aquestive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aquestive Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share 0.73 | Quarterly Revenue Growth 0.042 | Return On Assets (0.16) |
The market value of Aquestive Therapeutics is measured differently than its book value, which is the value of Aquestive that is recorded on the company's balance sheet. Investors also form their own opinion of Aquestive Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aquestive Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aquestive Therapeutics' market value can be influenced by many factors that don't directly affect Aquestive Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aquestive Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aquestive Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aquestive Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Price To Operating Cash Flows Ratio Analysis
Compare Aquestive Therapeutics and related stocks such as Evoke Pharma, Adamis Pharma, and Guardion Health Sciences Price To Operating Cash Flows Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EVOK | (145) | (145) | (8.3235) | (5.8048) | (3.0959) | (2.04) | (2.1671) | (3.864) | (5.9024) | (6.2709) | (9.924) | (1.4336) | (1.2773) | (0.7042) | (0.74) |
| DVAX | (1.1195) | (8.8152) | (11.0899) | (6.5568) | (6.0109) | (8.5827) | (1.4208) | (12.6921) | (4.3458) | (3.3977) | (4.8601) | 4.8754 | 21.4439 | 17.8961 | 18.79 |
| AMPH | 3.6657 | 3.6657 | (42.4242) | 2.255 | 23.1389 | 59.9003 | 21.6755 | 22.6249 | 24.1748 | 21.7011 | 16.5183 | 11.355 | 15.2544 | 16.2678 | 12.07 |
| LNTH | 5.2599 | 5.2599 | (324) | (7.8608) | 10.4003 | 3.7959 | 5.5513 | 13.9163 | 9.778 | 9.9478 | 44.5394 | 36.1613 | 12.3859 | 13.8652 | 14.56 |
| ANIP | (6.805) | (1.0276) | (1.0585) | (18.5678) | 28.0018 | 29.7191 | 25.2547 | 18.8793 | 7.8376 | 16.003 | 22.7572 | 175 | (20.964) | 8.3438 | 9.3 |
| IRWD | (12.2667) | (15.8898) | (16.9308) | (4.9205) | (13.4729) | (15.4084) | (87.1289) | (22.3456) | (22.3087) | 194 | 10.7553 | 7.2234 | 6.9863 | 9.6942 | 10.18 |
| ALKS | (3.0629) | (857) | 24.0214 | 753 | 753 | (293) | (132) | 438 | 46.105 | 44.4502 | 38.2429 | 36.8039 | 203 | 11.4887 | 12.06 |
| SHPH | (20.6 K) | (20.6 K) | (20.6 K) | (20.6 K) | (20.6 K) | (20.6 K) | (20.6 K) | (20.6 K) | (7.4 K) | (155.9 K) | (155.9 K) | (13.9 K) | (59.8809) | (10.3743) | (10.89) |
| LFCR | (789) | (789) | (789) | (789) | (789) | (789) | (789) | (789) | (789) | (789) | (789) | (789) | (789) | (789) | (389) |
| ORGO | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (11.5253) | (13.3191) | 119 | 19.1323 | 14.0749 | 17.3605 | 18.23 |
Aquestive Therapeutics and related stocks such as Evoke Pharma, Adamis Pharma, and Guardion Health Sciences Price To Operating Cash Flows Ratio description
My Equities
My Current Equities and Potential Positions
| Aquestive Therapeutics | AQST |
| Classification | Drugs |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.51
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.